title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
Conclusions | This study confirmed that | PMC10032012 | ||
Methods | PMC10032012 | |||
Animal models and treatments | IUA | A total of 32 female adult SPF BALB/C mice (HUNAN SJA Laboratory animal co., LTD), weighing 22–26 g and aged 6–8 weeks, were employed in this experiment. The mice were placed in a clean, cozy, air-conditioned space with unrestricted access to food and drink. The temperature, lighting, noise, ventilation and other condi... | PMC10032012 | |
Histological analysis | Histological examination was carried out in accordance with earlier studies [ | PMC10032012 | ||
Cytokine assays | Mouse serum was obtained by centrifugation at 1000x g for 20 min at 4 ° C, after which serum cytokine concentrations were measured using ELISA kits for IL-1β(Cat#SEA563Mu; mouse; Cloud-Clone Crop; sensitivity range: 15.6–1,000 pg/mL; concentration range used for generating calibration curves: 1,000, 500, 250, 125, 62.5... | PMC10032012 | ||
Q-PCR assays | As previously reported [ | PMC10032012 | ||
Western blot analysis | Standard methods were used to perform Western blotting [ | PMC10032012 | ||
Patient samples and treatments | organic gynecological diseases, IUA | FALLOPIAN TUBE, ADHESIONS, DISEASES, HYDROSALPINX | January 1, 2019 to June 30, 2020, a total of 125 patients diagnosed with IUA by hysteroscopy in the Jiangxi and Jiujiang maternal and child health hospital in China were enrolled. Patients with untreated IUA were included in I group, and the inclusion criteria were(i) age ranged from 18 to 40; (ii) IUA was the hysteros... | PMC10032012 |
DNA extraction and highthroughput sequencing | Vaginal secretions were collected from mice and patients in each group, and bacterial genomic DNA was extracted according to the instructions for use of DNA kit from Tiangen Biotech Co., Ltd. The nano drop spectrophotometer (NanoDrop; Thermo Fisher Scientifc, Inc.) to measure the concentration and quality of DNA. The 1... | PMC10032012 | ||
Statistical analysis | QIIME (v1.8.0, | PMC10032012 | ||
Acknowledgements | We would like to thank the Ethics Committee for approving this study and the JiangXi Natural Science Foundation and the National Natural Science Foundation of China for supporting this research. | PMC10032012 | ||
Author Contribution | T.T.C., Z.X.L. and X.R.D. designed the study and funded it.，Q.X., L.J.H, X.T. and Y.J.L. carried out the experiments, W.J.C., D.F.L. and J.W. sorted out the experimental data，F.W. and Y.K. finished writing the article. All authors read and approved the manuscript and agree to be accountable for all aspects of the resea... | PMC10032012 | ||
Funding | Open Access funding enabled and organized by Projekt DEAL.Grants from the JiangXi Natural Science Foundation helped to fund this work (grant no. 20192ACBL20034 and grant no. 20202ACBL206010). The National Natural Science Foundation of China (grant no.82260298 and grant no. 82060638) and Jiangxi Province “Double Thousan... | PMC10032012 | ||
Data Availability | Database bacteria for high-throughput sequencing in animal and clinical trials are available at the National Center for Biotechnology Information (NCBI), and accession number can be found below: PRJNA 882,985 and PRJNA 883,005, respectively ( | PMC10032012 | ||
Declarations | PMC10032012 | |||
Ethics approval and consent to participate | The animal study was approved by Ethical Committee of Nanchang Royo Biotech Co., Ltd (reference number RYE2019121702). All experiments were performed in accordance with relevant guidelines and regulations. The study is reported in accordance with ARRIVE guidelines ( The clinical experiment was approved by the Instituti... | PMC10032012 | ||
Consent for publication | Not applicable. | PMC10032012 | ||
Competing interests | The study was conducted in the absence of any business or financial relationships that could be interpreted as potential conflicts of interest. | PMC10032012 | ||
References | PMC10032012 | |||
Subject terms | pneumonia, weight loss | PNEUMONIA | Barium sulfate and iohexol are commonly used as contrast agents for videofluoroscopic swallowing study (VFSS). This study compared their usefulness as contrast agents in visualizing components of swallowing predictable of subsequent pneumonia and unintentional weight loss after VFSS. This was a randomized, controlled, ... | PMC10700337 |
Introduction | dysphagia, Dysphagia, pneumonia, weight loss | DYSPHAGIA, DYSPHAGIA, ASPIRATION PNEUMONIA, PNEUMONIA | Dysphagia is difficulty or inability to form or move the alimentary bolus from the mouth to the stomachVideofluoroscopic swallowing study (VFSS) has been considered one of the gold standard assessments for evaluating dysphagia, as it can provide detailed information of the anatomical landmarks of the patient as well as... | PMC10700337 |
Methods | This study was conducted in accordance with the Declaration of Helsinki and was reviewed and approved by the Institutional Review Board of the Yeungnam University Hospital (IRB NO.2021-07-021-002). Written informed consent was obtained from all participants. This study was not registered. | PMC10700337 | ||
Trial design | dysphagia, muscle mass, pneumonia, dehydration, infection, sepsis, weight loss | DYSPHAGIA, PNEUMONIA, PULMONARY DISEASE, DEHYDRATION, INFECTION, INFLAMMATION OR INFECTION, SEPSIS, ASPIRATION PNEUMONIA, DISEASES | This study was a randomized controlled trial with a crossover design conducted from September 2021 to March 2022 in a tertiary university hospital. Because various characteristics of the patients are associated with the development of aspiration pneumonia and unintentional weight loss (e.g., age, need for bronchial suc... | PMC10700337 |
Participants | The inclusion criteria were as follows: (1) patients who were admitted in a tertiary university hospital and referred to the Department of Physical Medicine and Rehabilitation for VFSS to evaluate the safety of swallowing, (2) patients who could maintain a sitting position during VFSS, (3) patients who could stay alert... | PMC10700337 | ||
Intervention | VFSS was performed using an X-ray flat-panel detector system (FPD, Zexira®, Toshiba, Tokyo, Japan). Swallowing images were digitally recorded at a rate of 30 frames/s from a lateral viewing plane. The VFSS protocol consisted of (1) 3-ml thin liquid (barium sulfate solution or iohexol) provided with a spoon, (2) 5-ml yo... | PMC10700337 | ||
Outcome measures | pneumonia, weight loss, community-acquired pneumonia | PNEUMONIA, SECONDARY, ASPIRATION PNEUMONIA, HOSPITAL-ACQUIRED PNEUMONIA, ASPIRATION PNEUMONIA, COMMUNITY-ACQUIRED PNEUMONIA | Development of subsequent pneumonia after VFSS during the follow-up period was the primary outcome of this study and secondary outcome was unintentional weight loss. A case of pneumonia was identified based on chest imaging and antibiotic prescription. Aspiration pneumonia is accepted as a part of the continuum of comm... | PMC10700337 |
Statistical analysis | pneumonia, weight loss | PNEUMONIA | This study is a preliminary study and required sample size was calculated using G*Power 3.1Statistical analyses were performed using the Statistical Package for Social Sciences (version 22.0; IBM Corp., Armonk, NY, USA). The Wilcoxon signed-rank test was used to compare the VFSS findings (PAS, FDS, and number of swallo... | PMC10700337 |
Discussion | dysphagia, comorbidity, pneumonia, fatigue, acute stroke, neurodegenerative diseases, pulmonary disease, weight loss, muscle fatigue | DYSPHAGIA, PNEUMONIA, ACUTE STROKE, NEURODEGENERATIVE DISEASES, ASPIRATION PNEUMONIA, PULMONARY DISEASE, DISEASES | No significant differences were observed in the PAS and FDS total scores according to the contrast agent used in the test. This might suggest that the difference in physical properties of the two contrast agents is not critical enough to make a difference in the anatomical depth to which food bolus penetrates when inge... | PMC10700337 |
Acknowledgements | The authors would like to thank Editage ( | PMC10700337 | ||
Author contributions | Conceptualization: S.K. and M.C.C.; Methodology: S.K., M.K., and M.C.C.; Formal analysis and investigation: S.K., M.K., and M.C.C.; Writing—original draft preparation: S.K., M.K., and M.C.C.; Writing—review & editing: S.K. and M.C.C.; Funding acquisition: S.K.; Resources: S.K. and M.C.C.; Supervision: S.K. | PMC10700337 | ||
Funding | The present study was supported by a National Research Foundation of Korea Grant funded by the Korean government (Grant No. NRF-2022R1F1A1072553). | PMC10700337 | ||
Data availability | The data that support the findings of this study are available from the corresponding author upon reasonable request. | PMC10700337 | ||
Competing interests | The authors declare no competing interests. | PMC10700337 | ||
References | PMC10700337 | |||
Background | inflammation, T2D, type 2 diabetes | INFLAMMATION, TYPE 2 DIABETES | While a low-carbohydrate diet (LCD) reduces HbA1c in patients with type 2 diabetes (T2D), the associated high intake of fat may adversely affect cardiovascular risk factors. To address this, we examined the effect of a non-calorie-restricted LCD high in fat on endothelial function and markers of low-grade inflammation ... | PMC10436534 |
Methods | T2D | VASODILATION | In an open-label randomized controlled trial, 71 patients with T2D were randomized 2:1 to either a LCD (< 20 E% carbohydrates, 50–60 E% fat) or a control diet (50–60 E% carbohydrates, 20–30 E% fat) for six months. Flow-mediated vasodilation (FMD) and nitroglycerine-induced vasodilation (NID) were assessed by ultrasound... | PMC10436534 |
Results | The FMD and NID were unaltered in both groups after six months, and there were no between-group differences in change of either FMD (p = 0.34) or NID (p = 0.53) in response to the interventions. The circulating hsCRP and IL-6 levels decreased only in response to LCD (both p < 0.05). However, comparing changes over time... | PMC10436534 | ||
Supplementary Information | The online version contains supplementary material available at 10.1186/s12933-023-01956-8. | PMC10436534 | ||
Keywords | Open access funding provided by University Library of Southern Denmark | PMC10436534 | ||
Introduction | obesity, T2D, inflammation, CVD, adiposity, T2D a LCD | OBESITY, CARDIOVASCULAR DISEASE, CVD, INFLAMMATION, ADIPOSITY, EVENTS, TYPE 2 DIABETES, ENDOTHELIAL DYSFUNCTION | One of the major causes of mortality in type 2 diabetes (T2D) is cardiovascular disease (CVD) [T2D management includes lifestyle changes involving both diet and physical activity and is important to improve glycemic control and decrease risk of CVD [Along with endothelial dysfunction, circulating markers of low-grade i... | PMC10436534 |
Methods | PMC10436534 | |||
Study design and participants | T2D | As previously reported [Briefly described, the inclusion criteria included an established diagnosis of T2D [Out of 345 persons eligible for screening [Informed consent was obtained from all individuals before participation. The study was approved by the Regional Committees on Health Research Ethics for Southern Denmark... | PMC10436534 | |
Diet intervention and physical activity | This was a free-living study and no food was provided to the participants. The LCD group was instructed to follow a diet consisting of a maximum of 20 E% carbohydrates, 50–60 E% fats 25–30 E% protein with a recommendation of a high intake monounsaturated fatty acids (MUFAs) and as low intake of saturated fatty acids (S... | PMC10436534 | ||
Assessment of flow-mediated vasodilation (FMD and nitroglycerine induced dilation (NID) | FMD and NID in the brachial artery were assessed by a single investigator at baseline and after 6 months of diet change using a Phillips iE33 ultrasound machine with a L15-7io linear array transducer and automated settings for FMD/NID. The participant’s right arm was examined in the morning after an overnight fast, min... | PMC10436534 | ||
Other outcome measures | All participants attended three visits during the study (baseline, 3 months and 6 months) with collection of fasting blood samples for measuring lipids, insulin, HbA1c, fasting plasma glucose and blood-ketones as reported [Serum hsCRP was measured in duplicates by an in-house ELISA using commercially available monoclon... | PMC10436534 | ||
Statistical analysis | SE | CVD, REGRESSION, SECONDARY, REGRESSIONS | Statistical analysis was done with STATA for Windows (STATA 16.0, StataCorp LLC, Texas, USA). The vascular function was one of the pre-specified secondary outcomes in this study. The estimation of the sample size was based on the primary outcome, HbA1c, and this showed that 36 in the LCD group and 18 in the control gro... | PMC10436534 |
Results | PMC10436534 | |||
Baseline characteristics | SD, diabetes | DIABETES | Among study participants with valid FMD measurements at baseline (n = 70), the two groups were comparable with respect to age, duration of diabetes, HbA1c, gender distribution, smoking status, lipid levels and BMI (Table Baseline characteristicsData are means ± SD or number (%) | PMC10436534 |
Changes in clinical parameters | As reported previously [ | PMC10436534 | ||
Measures of endothelial function | flow-mediated vasodilation | VASODILATION | At baseline, 41 of 49 (84%) in the LCD group and 20 of 21 (95%) in the control group had FMD < 7.1% (p = 0.42), and 20 of 48 (42%) in the LCD group and 14 of 21 (67%) in the control group had NID < 15.6% (p = 0.06). These proportions did not change significantly after 6 months (data not shown). In the LCD group, the re... | PMC10436534 |
Measures of low-grade inflammation | CVD | In the LCD group, both hsCRP (p = 0.004) and IL-6 (p = 0.013) decreased after 6 months on the diet, whereas no significant changes were seen in the control group (Fig. Changes in Using Spearman’s rank correlation coefficient in the total cohort (n = 70) at baseline, we found that plasma Il-6 levels correlated positivel... | PMC10436534 | |
Adjusting for covariates correlated to FMD or NID | CVD | To adjust the analysis for between-group differences in CVD risk factors at baseline, we evaluated the relationship between FMD and NID and all the CVD risk factors listed in Table When adjusting our analysis for these significant covariates, there was, however, still no effect of LCD for 6 months on FMD (adjusted MDIC... | PMC10436534 | |
Description of changes in cholesterol and blood pressure lowering medication | There were no changes in cholesterol-lowering treatment during the study, except for two LCD participants who reported sporadic use of statins. In the LCD-group, one patient treated with both an angiotensin-converting enzyme (ACE) inhibitor and an angiotensin II receptor blocker (ARB) had the ACE inhibitor discontinued... | PMC10436534 | ||
Discussion | obesity, inflammation, T2D | CVD, INFLAMMATION, VASODILATION, OBESITY | In this second study from an open-label RCT [Population-based studies have provided evidence that correction of a suboptimal diet may be a powerful approach to reduce the risk of CVD [There might, however, be transient effects of an increased intake of fat on endothelial function that are attenuated or eventually lost ... | PMC10436534 |
Acknowledgements | Diabetes | HANSEN, DIABETES | We would like to thank L. Hansen and C. B. Olsen, the Steno Diabetes Center Odense, Odense University Hospital, as well as A. R. Madsen, Department of Endocrinology, Odense University Hospital, for their skilled technical assistance. We also owe great thanks to professor DHJ Thijssen and ACCM van Mil for expertise and ... | PMC10436534 |
Author contributions | CDH | EMG-K, CDH, AK, HB-N, MHO, and KH contributed to the conception and design of the study. EMG-K, CDH, MBH, and JMJ conducted the intervention study. EMG-K, TBO and AH contributed to the ultrasound and biomarker analyses. EMG-K, CDH, AK, HB-N, MHO, TBO, AH and KH analysed and interpreted data, and EMG-K and KH wrote the ... | PMC10436534 | |
Funding | Diabetes | DIABETES | Open access funding provided by University Library of Southern Denmark. The present study was supported by grants from the Region of Southern Denmark, Odense University Hospital, the Danish Diabetes Academy funded by the Novo Nordisk Foundation, the Novo Nordisk Foundation, University of Southern Denmark, the AP Møller... | PMC10436534 |
Availability of data and materials | The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. | PMC10436534 | ||
Declarations | PMC10436534 | |||
Ethics approval and consent to participate | Informed consent was obtained from all individuals before participation. The study was approved by the Regional Committees on Health Research Ethics for Southern Denmark and was performed in accordance with the Declaration of Helsinki Declaration II. The RCT was registered at ClinicalTrials.gov (NCT03068078). | PMC10436534 | ||
Consent for publication | I, the undersigned, give my consent for the publication to be published in the Cardiovascular Diabetology Journal. | PMC10436534 | ||
Competing interests | AK reports speaker honorarium from Norgine, Siemens and Nordic Bioscience, outside the submitted work. | PMC10436534 | ||
References | PMC10436534 | |||
Abstract | Nicole E. Billingy and Vashti N. M. F. Tromp contributed equally to this work as joint first authors.Annemarie Becker-Commissaris, Corina J. G. van den Hurk and Iris Walraven contributed equally to this work as joint senior authors. | PMC10699799 | ||
Background | PROM, cancer, lung cancer | LUNG CANCER, CANCER | Previous studies using patient-reported outcomes measures (PROMs) to monitor symptoms during and after (lung) cancer treatment used alerts that were sent to the health-care provider, although an approach in which patients receive alerts could be more clinically feasible. The primary aim of this study was to compare the... | PMC10699799 |
Methods | lung cancer, PROM | LUNG CANCER, REGRESSION, LUNG | The SYMPRO–Lung trial is a multicenter randomized controlled trial using a stepped wedge design. Stage I-IV lung cancer patients in the reactive and active groups reported PROM symptoms weekly, which were linked to a common alerting algorithm. HRQOL was measured by the EORTC QLQ-C30 at baseline and after 15 weeks. Line... | PMC10699799 |
Results | A total of 515 patients were included (160 active group, 89 reactive group, 266 control group). No differences in HRQOL were observed between the reactive and active group (summary score: unstandardized beta [B] = 0.51, 95% confidence interval [CI] = -3.22 to 4.24, Cohen | PMC10699799 | ||
Conclusions | lung cancer, cancer, Lung cancer, cancer deaths | LUNG CANCER, CANCER, LUNG CANCER, LUNG | Weekly PRO symptom monitoring statistically and clinically significantly improves HRQOL in lung cancer patients. The logistically less intensive, reactive approach may be a better fit for implementation.Lung cancer is the second most common cancer diagnosed worldwide, and the most common cause of cancer deaths per year... | PMC10699799 |
Methods | PMC10699799 | |||
Study design and study sample | We conducted a multicenter RCT using a stepped wedge design, the details of which have been reported previously (The stepped wedge cluster randomized design involved sequential transition of the participating hospitals in a randomized order. Over a period of 16 months, 13 Dutch hospitals (3 academic and 10 nonacademic)... | PMC10699799 | ||
Intervention | lung cancer, Toxicity | LUNG CANCER, ADVERSE EVENT | There were 2 intervention groups differing in the way the alerts were handled; 1 reactive group in which patients themselves received an alert via a pop-up notification and (secure) e-mail containing the advice to contact the hospital within 24 hours on weekdays; 1 active group in which the health-care providers receiv... | PMC10699799 |
Control group | Patients in the control group received care as usual. This consisted of the standard procedure at their hospital for assessing and documenting symptoms (predominantly discussing symptoms with their health-care provider during outpatient visits and a documentation in their medical record). | PMC10699799 | ||
Study measures | PMC10699799 | |||
Primary outcomes | Cancer | SECONDARY, CANCER | The primary outcome was the mean change from baseline to 15 weeks (T1) after the start of treatment in HRQOL as assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) (Additional information on the EORTC QLQ-C30 scales, interpretation of clinically relev... | PMC10699799 |
Statistical analysis | REGRESSION | The trial protocol included a sample size of 584, yielding 80% power to detect a Cohen’s Data were analyzed on an intention-to-treat basis. Patient characteristics are presented as proportions: mean (SD). Differences in baseline characteristics and HRQOL were compared using independent samples Comparisons were made bet... | PMC10699799 | |
Results | LUNG | A total of 515 patients completed the baseline questionnaire (CONSORT diagram of the Symptom Reporting with Patient-Reported Outcomes–Lung trial. | PMC10699799 | |
Baseline characteristics | ONCOLOGY | Most baseline sociodemographic and clinical characteristics were balanced across groups (Baseline characteristicsImmunotherapy combined: immunotherapy (combined with chemotherapy or chemoradiation and/or surgery and/or targeted therapy. Radiotherapy combined: radiotherapy (combined with surgery). Chemotherapy combined:... | PMC10699799 | |
Symptom reporting and alert interventions | Of the 249 intervention patients, 244 (98%) completed at least 1 weekly symptom checklist. In total, 2412 symptom checklists were completed by the intervention group (see | PMC10699799 | ||
Primary HRQOL outcomes | PMC10699799 | |||
Noninferiority analyses (reactive vs active intervention group) | cancer stage | REGRESSION, ONCOLOGY | The reactive and active intervention groups were comparable in terms of baseline summary score (mean = 76.6 [SD = 16.0] in the reactive group; mean = 75.8 [SD = 14.1] in the active group; Multivariable linear regression analysis for health-related quality of life from baseline to 15 weeks reactive vs active interventio... | PMC10699799 |
Superiority analyses (intervention vs control group) | cancer stage | REGRESSION | The intervention and control groups were comparable in terms of baseline summary score and physical functioning (Multivariable linear regression analysis for health-related quality of life from baseline to 15 weeks intervention vs control group including confoundersEORTC quality-of-life score and functioning scales: hi... | PMC10699799 |
Secondary HRQOL | For the majority of the remaining QLQ-C30 scale scores, mean differences between the reactive and active intervention groups also reached an effect size below our threshold of 0.2, indicating noninferiority (The mean (change) scores for all functioning and symptom scales can be found in | PMC10699799 | ||
Sensitivity analyses (multiple imputation) | Multiple imputation analyses did not result in statistically significantly different associations (see | PMC10699799 | ||
Discussion | lung cancer | LUNG CANCER, SECONDARY, RECRUITMENT, METASTATIC CANCER | In this trial assessing the effect of patient-reported symptom monitoring on HRQOL in lung cancer patients, we observed that a reactive approach (patient receives alert) and an active approach (health-care provider receives alert) are equally effective on HRQOL. Furthermore, we confirmed that patient-reported outcomes ... | PMC10699799 |
Supplementary Material | Click here for additional data file. | PMC10699799 | ||
Acknowledgements | ONCOLOGY | We thank the patients for their participation. We appreciate and acknowledge the helpful contributions made by Evalien Veldhuijzen, Chermaine Noortman-van Meteren, and the research nurses and specialized nurses of the participating hospitals.The funder had no role in the design of the study; the collection, analysis, o... | PMC10699799 | |
Data availability | LUNG | Data from the SYMPRO–Lung study are available upon request and permission by the principal investigators (PIs). Please contact Nicole Billingy ( | PMC10699799 | |
Author contributions | Nicole E. Billingy, MSc (Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Project administration; Resources; Software; Validation; Visualization; Writing—original draft; Writing—review & editing), Vashti N.M.F. Tromp, MSc (Conceptualization; Data curation; Investigation; Methodology; Proje... | PMC10699799 | ||
List of contributors | Cancer | PULMONARY DISEASES, BREDA, CANCER | In addition to the authors, the SYMPRO-Lung Consortium consists of the following other members: N.C. van Walree, MD, Amphia Hospital, Department of Pulmonary Medicine, Breda, the Netherlands; K. de Jaeger, MD, Catharina Hospital Eindhoven, Department of Catharina Cancer Institute, Eindhoven, the Netherlands; S. Samii, ... | PMC10699799 |
Funding | This work was supported by Zorg Innovatiefonds (Innovatiefonds Zorgverzekeraars, Sparrenheuvel 16, Postbus 304, 3700 AH Zeist), Roche (Roche Nederland B.V., Beneluxlaan 2A, 3446 GR Woerden), and Stichting Kwaliteitsgelden Medisch Specialisten (SKMS, Mercatorlaan 1200, Postbus 20057, 3502 LB Utrecht). | PMC10699799 | ||
Conflicts of interest | Corina J.G. van den Hurk: IKNL received research funding from for-profit health care company AstraZeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Ipsen and Merck. All other authors have no conflicts of interest. The rest of the SYMPRO-Lung Consortium has nothing to declare. | PMC10699799 | ||
References | PMC10699799 | |||
Background | fatigue, visual impairment | Over 50% of adults with visual impairment experience severe fatigue. Therefore, we developed a guided E-health intervention based on cognitive behavioral therapy and self-management to reduce fatigue in this population. This pilot study evaluated the usability, feasibility, fidelity and potential effectiveness of E-ner... | PMC10655361 | |
Methods | fatigue, visual impairment, Fatigue | E-nergEYEze was developed by a design team and customized by conducting a pilot study using an iterative development strategy. The intervention was first tested in a usability study among adults with visual impairment (n = 5). Participants were asked to think-aloud while exploring the intervention features and a semi-s... | PMC10655361 | |
Results | fatigue | The usability study resulted in adjustments to content and lay-out with regard to optically shortened text sentences, separate pages for information and assignments with one read-aloud audio and an additional descriptive explanation of page content. Digital challenges were overcome with mandatory computer training and ... | PMC10655361 | |
Conclusion | fatigue, visual impairment | We developed, evaluated and optimized E-nergEYEze by applying a user-centered and iterative approach. E-nergEYEze showed a promising trend to reduce fatigue severity and impact of fatigue and to increase cognitive behavioral therapy skills. The study methods were feasible and the fidelity of the intervention protocol w... | PMC10655361 | |
Trial registration | International Clinical Trial Registry Platform: NL7764. Date registered: 28-05-2019. | PMC10655361 | ||
Keywords | PMC10655361 | |||
Introduction | chronic diseases with cognitive behavioral, vision loss, fatigue, visual impairment | The global population with vision loss has increased to over three billion people [There is evidence on effective interventions to treat fatigue in other chronic diseases with cognitive behavioral therapy (CBT) and self-management (SM) [People with visual impairment are increasingly using technology as a tool for safet... | PMC10655361 | |
Methods | PMC10655361 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.